Biodesix won the BizIQ award, 2016 Innovative Company of the Year.
The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision
Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.
Biodesix will present data from three studies at SITC's annual meeting.
Humana, Medical Mutual of Ohio and Preferred One independently determined and published a policy stating that VeriStrat can be considered medically necessary for patients with (NSCLC)
Data from an independent study demonstrated the clinical utiity of Biodesix' VeriStrat and GeneStrat tests.
Independent Study Data supports clinical use of Biodesix’s blood-based tests at CHEST conference.
VeriStrat® Test identifies patients with squamous cell carcinoma of the lung who are more likely to have improved survival on Afatinib therapy.
Biodesix's VeriStrat test identifies T790M-mutated advanced non-small cell lung cancer patients who are more likely to have improved progression-free survival on third generation EGFR-TKI therapy
Multi-institutional data supporting clinical use of Biodesix blood tests was presented at the IASCL Chicago thoracic conference